The Clock Is a Clause: Why Time Decides Value in Out-Licensing Generic Injectables

By Mahesh Hiremath, Global Head – Business Development, Invengene Private Limited

More than two decades in pharmaceutical business development have taught me that a licensing opportunity rarely remains static between the first commercial discussion and the day a product reaches the market.

I have seen products with strong science, attractive market potential and capable partners lose some of their original commercial value simply because the transaction and the subsequent execution took longer than expected. The reasons are rarely dramatic. A term sheet takes another round of negotiation. A diligence response waits for the right person. A dossier transfer is delayed by a missing country-specific module. A regulatory query takes a few weeks longer to close.

Individually, these delays can appear insignificant. In aggregate, they can change the economics of an opportunity.

This is particularly true in generic injectables, where the window for commercial advantage can be narrow. By the time a partnership moves from initial agreement to filing or launch, competitors may have entered, a tender cycle may have passed, or the pricing environment may have shifted.

The lesson I have taken from these experiences is straightforward: in out-licensing, time is not simply an operational consideration. It is part of the value being negotiated.

Why injectable opportunities have narrow windows

Generic injectables are particularly sensitive to timing. Sterile manufacturing requirements and formulation complexity can limit the number of companies capable of developing and filing a product, making the first wave of entrants especially valuable. But that advantage does not last indefinitely. As more competitors enter, pricing pressure can increase and the opportunity to establish market share can become harder.

The dynamics vary across markets. In regulated markets, loss-of-exclusivity dates are generally known well in advance, creating a commercial window towards which multiple companies are working. A difference of a few weeks in readiness can therefore matter. In emerging markets, registration timelines tend to be longer and less predictable, making an early start equally important because a delay at the beginning can compound through the regulatory process.

Hospital and government tenders introduce another dimension. These markets operate around defined submission and procurement cycles, and missing a window can mean waiting for the

next one. Supply shortages can create opportunities as well, but those windows can close quickly as supply normalises or competitors respond.

Across these situations, the lesson is the same: the market will not wait for the deal.

Companies generally need to manage two types of strategic vision within their portfolios. One is built around standard technology products that may offer lower margins but provide sustainable and predictable revenue over time. The other is built around products with a limited commercial window, where patent timing, regulatory readiness, development speed and market entry are critical to capturing value. Ideally, a company should maintain a balanced portfolio: approximately 40% comprising lower-margin but steady and sustainable products, and 60% comprising high-margin, time-sensitive opportunities that must be continuously added, developed and commercialised within the right window. This balance gives a company a stronger foundation for long-term operations. The 40% portion supports revenue continuity, while the portfolio, R&D and commercial teams must consistently deliver newer products within the 60% opportunity window. In the B2B out-licensing segment, therefore, timing is not only important — it is often the factor that determines whether the full commercial value of an opportunity can be realised.

Where the time actually goes

Deals rarely lose time because of one dramatic failure. More often, time leaks away through routine activities: term sheets that are reopened after they seemed settled, diligence questions that wait days for an answer, dossier transfers held up by missing modules, regulatory queries that take longer to address than necessary, or manufacturing sites that are not quite ready when the documentation is.

None of these events is unusual. The challenge is that each stage depends on another, and the time between those stages can be difficult to see. One team completes its responsibility and assumes the next team will pick up the work. A decision is waiting somewhere in between. Everyone remains busy, but the clock continues to run.

In my experience, this is rarely about incompetence. Most people understand their responsibilities and are trying to move the work forward. The problem is that the elapsed time between responsibilities often belongs to no one.

That is where a commercially attractive opportunity can quietly lose momentum.

Agree on the clock

One of the most useful things two partners can do is agree on turnaround-time benchmarks at the beginning of a deal. How many working days should each side take to respond to term-sheet comments? How quickly will diligence questions be

answered? How soon after signature will the dossier be handed over? What is the expected turnaround for regulatory queries?

The exact numbers will vary by transaction. What matters is that both sides agree to them and understand that they are part of the joint project plan. A benchmark that exists only in one partner's expectations is simply a hope. Once it is agreed and documented, it becomes a shared standard that either side can refer to without turning every delay into an accusation.

It also forces useful honesty early. If one side cannot commit to a reasonable turnaround for a critical activity such as dossier transfer, it is far better to understand that in the first few weeks than several months later, when the commercial opportunity may already have moved.

Make progress visible

Agreeing on timelines is only useful if someone is watching them. Milestone tracking is therefore less about creating another administrative process and more about ensuring that both organisations have the same view of where a deal stands.

The technology matters less than the discipline. A shared tracker, project dashboard or well-maintained spreadsheet can work, provided both partners are looking at the same information, reviews take place on a fixed cadence, and the activities leading to a milestone are visible.

That last point is important. By the time a filing date is visibly missed, it may already be too late to recover the lost time. If the activities underneath that filing are being tracked, a delay can be identified while there is still an opportunity to intervene.

Visibility also changes behaviour. When a diligence response has been outstanding for ten days and both organisations can see it, it becomes much harder for the delay to remain invisible.

Escalate before the delay becomes a dispute

Even well-run transactions encounter delays. What separates a manageable delay from a damaging one is often how quickly the issue reaches someone with the authority to resolve it.

An effective escalation mechanism should therefore be agreed at the beginning of the partnership. Both sides should know what constitutes a meaningful delay, when an issue moves to the next level, who becomes involved and how quickly a decision is expected.

Done properly, escalation is not a complaint. It is an early-warning mechanism that protects the project and the relationship.

The strongest deals can take this further by putting time directly into the commercial structure through milestone-linked payments, launch commitments and defined rights if agreed timelines lapse. When both partners benefit from moving faster and understand the consequences of moving slower, the clock becomes a shared commercial responsibility.

Speed becomes part of the partnership

There is another dimension to speed that is easy to underestimate. Partners remember how an organisation behaves when a deal becomes complicated. They remember who responded quickly, whose dossier arrived complete and which team raised a problem early rather than allowing it to become a late-stage surprise.

Over time, reliable execution becomes reputation. In business development, that reputation matters because today's partnership can influence tomorrow's opportunity. A company that consistently demonstrates that it can move from agreement to execution with discipline becomes easier for counterparties to trust.

That is why I do not see speed simply as project management. It is a capability, and it becomes part of how an organisation is perceived.

The clock is part of the value

Licensing discussions naturally focus on territory, price, exclusivity, milestones and supply. Those terms remain fundamental, but in generic injectables their value is also influenced by what happens between agreement and market entry.

A strong molecule does not guarantee a strong commercial outcome. An attractive market does not remain attractive indefinitely. And a well-negotiated agreement cannot recover every week lost during execution.

At Invengene, we increasingly think about the timeline as part of what we are licensing, rather than something that simply happens around the licence. That means asking not only whether we can do the deal, but how quickly we can execute it, where the critical dependencies are, who owns each part of the clock and what happens when an agreed timeline moves.

After more than two decades in pharmaceutical business development, that is perhaps the lesson I would leave with any team working on an out-licensing opportunity in generic injectables.

The molecule determines whether a deal is possible. The market determines the size of the opportunity. But the clock determines how much of that opportunity the partnership can capture.

#PharmaceuticalLicensing #GenericInjectables #BusinessDevelopment #CXOLanes